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PARP inhibitors (PARPis) are being used in patients
with BRCA1/2 mutations. However, doubly deficient
BRCA1–/–53BP1–/– cells or tumors become resistant to
PARPis. Since 53BP1 or its known downstream effec-
tors, PTIP and RIF1 (RAP1-interacting factor 1 homolog),
lack enzymatic activities directly implicated in DNA
repair, we decided to further explore the 53BP1-dependent
pathway. In this study, we uncovered a nuclease, Artemis,
as a PTIP-binding protein. Loss of Artemis restores PARPi
resistance in BRCA1-deficient cells. Collectively, our data
demonstrate that Artemis is the major downstream effec-
tor of the 53BP1 pathway, which prevents end resection
and promotes nonhomologous end-joining and therefore
directly competes with the homologous recombination
repair pathway.
Supplemental material is available for this article.
Received September 9, 2014; revised version accepted No-
vember 4, 2014.
Eukaryotic cells have two main repair pathways for DNA
double-stranded breaks (DSBs); namely, the nonhomolo-
gous end-joining (NHEJ) and homologous recombination
(HR) pathways. Which pathway is selected for DSB repair
under certain circumstance is critically important for
genome maintenance (for review, see Chapman et al.
2012). In particular, understanding the detailed regulation
of DNA repair pathway choice will help us design better
therapies for cancer patients. For example, a major break-
through in the targeted treatment of BRCA1/2 mutant
cancers is the use of PARP inhibitors (PARPis), which
display ‘‘synthetic lethality’’ with BRCA1 or BRCA2
deficiency (Bryant et al. 2005; Audeh et al. 2010; Chan
and Mok 2010; Tutt et al. 2010). Unexpectedly, loss of
53BP1 renders these BRCA1-deficient tumors resistant to
PARPis, suggesting that 53BP1 and BRCA1 compete with
each other to influence the pathway choice for DSB repair
(Bouwman et al. 2010; Bunting et al. 2010; Jaspers et al.
2013). However, despite extensive studies in the past
decade, it remains elusive precisely how 53BP1 acts in
DNA repair, since it does not possess any enzymatic
activities that would be required for DNA repair. The
current hypothesis is that 53BP1 is an adaptor protein
that does not act directly in DNA repair. Instead, it may
recruit other proteins to the sites of DNA breaks to
facilitate NHEJ repair, which competes with HR repair.
In support of this hypothesis, several research groups
demonstrated that RIF1 (RAP1-interacting factor 1 homo-
log), is at least one of the key factors that acts downstream
from 53BP1 and counteracts BRCA1’s functions in DNA
repair (Chapman et al. 2013; Di Virgilio et al. 2013;
Escribano-Diaz et al. 2013; Feng et al. 2013; Zimmermann
et al. 2013). However, RIF1 loss seems insufficient to
rescue the HR defect in BRCA1-deficient cells. A more
recent study showed that ablation of PTIP provides addi-
tional or sustained resection required for rescuing HR
repair in BRCA1-deficient cells, indicating that PTIP and
RIF1 may inhibit different resection steps during HR
repair (Callen et al. 2013). Unfortunately, RIF1 and PTIP
again are adaptor proteins, since they also lack any enzy-
matic activities that would be involved in DNA repair.
We thus decided to further explore the 53BP1-depen-
dent pathway, focusing on the identification of down-
stream effector proteins that directly participate in DNA
repair. PTIP is known to be involved in DNA repair but
also has a separate role in transcriptional regulation
through its association with MLL2/MLL3 histone meth-
yltransferase complexes (Cho et al. 2007; Munoz et al.
2007; Patel et al. 2007; Gong et al. 2009). In this study, we
uncovered a nuclease, Artemis, as a PTIP-binding protein.
Artemis is an evolutionally conserved nuclease (for re-
view, see Cattell et al. 2010). Defects in Artemis lead to
a severe combined immunodeficiency disorder (SCID)
known as radiosensitive SCID (RS-SCID) syndrome
(Moshous et al. 2001). Artemis has endonuclease activity
in vivo and is a known component of the NHEJ pathway
(Ma et al. 2002). Here, we show that Artemis is the major
downstream effector of the 53BP1 pathway, which trims
DNA ends and promotes NHEJ and therefore directly
competes with the HR repair pathway.
Results and Discussion
PTIP plays important roles in the cellular response to
DNA damage (Munoz et al. 2007; Gong et al. 2009).
However, PTIP lacks any enzymatic activity that would
be directly involved in DNA repair. Thus, we used a
modified tandem affinity purification (TAP) coupled with
mass spectrometry (TAP-MS) approach that was estab-
lished in our laboratory (Gong et al. 2010; Wang et al.
2011, 2013) to identify novel PTIP-associated proteins.
Excitingly, MS analysis revealed not only several known
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PTIP-binding proteins—including 53BP1, PA1, and com-
ponents of histone methyltransferase complexes (e.g.,
MLL3 and NCOA6)—but also a nuclease, Artemis (also
called SNM1C), as major PTIP-associated proteins (Fig.
1A). Furthermore, we identified PTIP as an Artemis-
associated protein in a reverse TAP-MS analysis (Fig.
1A). We further confirmed this interaction by coimmu-
noprecipitation experiment (Fig. 1B; Supplemental Fig.
S1). UsingMyc-tagged wild-type PTIP and a series of PTIP
BRCT domain deletion mutants (D1–D6, each with a de-
letion of one of the six BRCT domains in PTIP) that we
previously generated (Gong et al. 2009), we showed that
deletion of the second BRCT domain (D2) abolished the
PTIP/Artemis interaction, indicating that the BRCT2
domain is important for the binding of PTIP
to Artemis (Fig. 1C). Furthermore, using
a bacterially expressed and purified GST-
fused BRCT2 of PTIP protein, we showed
that the PTIP BRCT2 binds to Artemis in
vitro (Fig. 1D), indicating that the BRCT2
domain of PTIP is necessary and sufficient
for its binding to Artemis.
A recent study demonstrated that PTIP
acts downstream from 53BP1, and PTIP
deficiency restored PARPi resistance in
a BRCA1-deficient background (Callen et al.
2013). Indeed, we showed that codepletion
of PTIP and BRCA1 led to cellular resis-
tance to PARPis (Fig. 1E). Moreover, recon-
stitution of wild-type PTIP resensitized
these cells to PARPis, but reconstitution
with the BRCT2 deletion mutant of PTIP
failed to do so (Fig. 1E). These data indicated
that the BRCT2 domain of PTIP, which is
required for its interaction with Artemis, is
important for the function of PTIP in coun-
teracting HR repair.
Since Artemis possesses endonuclease
activities (Ma et al. 2002), we reasoned that
Artemis may use its nuclease activity to trim
DNA ends and therefore facilitate NHEJ and
prevent DNA end resection and HR repair.
Indeed, we showed that loss of Artemis ren-
ders BRCA1-deficient cells resistant to PARP
inhibition (Fig. 2A). Furthermore, damage-in-
duced RPA2 foci (marker of end resection) or
RAD51 foci (marker for HR repair) were re-
duced in BRCA1-depleted cells but were re-
established in BRCA1/Artemis-codepleted
cells (Fig. 2B,C), indicating that Artemis acts
to prevent end resection and suppress RAD51-
dependent HR repair. In addition, after PARPi
treatment, the number of radial chromosomes
increased in BRCA1-deficient cells, while this
phenotype was partially rescued in Artemis-
codepleted cells (Fig. 2D).
The nuclease activity of Artemis is re-
quired for opening the hairpins that form on
DNA ends during V(D)J recombination (Ma
et al. 2002). To assess whether the nuclease
activity of Artemis is critical for this function
in counteracting HR repair, we generated
HeLa cells that stably express siRNA-resis-
tant wild-type Artemis or the nuclease-inac-
tivemutant (H35AD37N) (Fig. 2E, right panel)
of Artemis so that we can express exogenous
Artemis when the endogenous Artemis is
depleted by siRNA. As shown in Figure 2E
(left panel), reconstitution of wild-type Arte-
mis resensitized cells to PARPis, while the
nuclease-inactive mutant (H35AD37N) of
Artemis failed to do so. Additionally, we
Figure 1. PTIP interacts with Artemis through its BRCT2 domain. (A) Lists of PTIP or
Artemis-associated proteins identified by mass spectrometric analysis. (B) Endogenous
PTIP interacts with Artemis. HeLa cell lysates were prepared and immunoprecipitated
with PTIP antibody. Immunoprecipitates were blotted using antibodies as indicated. (C)
The BRCT2 domain of PTIP is required for PTIP/Artemis interaction. 293T cells were
transfected with plasmids encoding SFB-tagged Artemis together with plasmids encod-
ing deletion mutants of Myc-tagged PTIP. Precipitation reactions were conducted using
S protein beads and then subjected to Western blotting using the indicated antibodies.
D1–D6 are PTIP BRCT domain deletion mutants, each of which has a deletion of one of
the PTIP BRCT domains. (D) PTIP BRCT2 specifically binds to Artemis. Beads coated
with bacterially expressed GST-fused PTIP BRCT2 were incubated with cell lysates
containing exogenously expressed SFB-tagged Artemis. Immunoblotting experiments
were carried out using the indicated antibodies. (E) The BRCT2 domain of PTIP
counteracts HR repair. HeLa cells were reconstituted with empty vector, siRNA-
resistant PTIP wild type, or the PTIP D2 mutant. Next, HeLa cells as well as these
reconstituted cells were transfected with the indicated siRNAs and treated with 1 mM
PARPis. Colony formation was quantified relative to colonies formed in untreated cells
from the same setting. (Left panel) Data are represented as the mean 6 SEM (n = 3).
(Right panel) Knockdown efficiency of PTIP or BRCA1 was confirmed by Western
blotting with the indicated antibodies.
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observed that reconstitution of the nucle-
ase-inactive mutant of Artemis also in-
creased RPA foci formation compared with
those that reconstitute with wild-type Ar-
temis (Fig. 2B). We reproducibly confirmed
the above data by using Artemis knockout
cells reconstituted with wild-type and nu-
clease-inactive mutant (H35AD37N) Arte-
mis (Supplemental Fig. S2A), suggesting
that Artemis and its nuclease activity are
required for the prevention of end resection
and HR repair.
The BRCT domain is a phosphoprotein-
binding domain (Manke et al. 2003; Yu et al.
2003). The interaction between PTIP and
Artemis was abolished following treatment
with l protein phosphatase, suggesting that
the interaction between PTIP and Artemis
is phosphorylation-dependent (Fig. 3A). Us-
ing a series of Artemis deletion mutants, we
mapped the PTIP-binding region to the very
C terminus of Artemis (residues 641–660)
(Fig. 3B; data not shown). To identify poten-
tial phosphorylation sites of Artemis, we
isolated Artemis protein from cells with or
without DNA damage and performed MS
analysis to identify all potential phosphory-
lation sites on Artemis. A total of 13 phos-
phorylation sites were identified, with six
sites showing up only in damaged cells
(Supplemental Fig. S3). We mutated each
of these six residues. We found that muta-
tion of all six serine/threonine sites abol-
ished the PTIP/Artemis interaction, while
mutation of residue Thr656 greatly dimin-
ished the PTIP/Artemis interaction (Fig.
3C). Mutation of the other four serine resi-
dues also affected the PTIP/Artemis inter-
action (Fig. 3C), suggesting that while the
Thr656 site is a major phosphorylation site
involved in the PTIP/Artemis interaction,
the other four residues also contribute to
this interaction. We generated HeLa cells
stably expressing siRNA-resistant wild-type
Artemis or the substitution mutant of Ar-
temis in which these phosphorylation sites
(serine or threonine) are replaced by Ala-
nine. As shown in Figure 3D, the expression
of siRNA-resistant wild-type Artemis fully
restored PARPi sensitivity in Artemis/
BRCA1-codepleted cells, whereas the expres-
sion of the Artemis 6S/TAmutant failed to do
so, indicating that the PTIP/Artemis interac-
tion is critical for antagonizing HR repair. We
further investigated how the phosphorylation
of Artemis and its interaction with PTIP are
regulated. In this regard, we found that the
interaction ofArtemiswith PTIPwas induced
by DNA damage (Fig. 3E,F), which is mainly
dependent on ATM kinase (Fig. 3F).
Since PTIP localizes to DNA damage sites
(Munoz et al. 2007; Gong et al. 2009), we
wanted to determine whether Artemis
could also localize to DNA damage sites.
We did not have an anti-Artemis antibody
Figure 2. The nuclease Artemis prevents DNA end resection and HR repair. (A) Loss of
Artemis renders BRCA1-deficient cells resistant to PARP inhibition. HeLa cells were
transfected with the indicated siRNAs and treated with 1 mM PARPis. Colony
formation was quantified relative to colonies formed in untreated cells from the same
setting. Data are represented as the mean 6 SEM (n = 3). Knockdown efficiency of
Artemis or BRCA1 was confirmed by Western blotting with the indicated antibodies. (B)
Artemis suppresses RAD51-dependent HR repair. HeLa cells were transfected with the
indicated siRNAs. At 3 h post-irradiation (10 Gy), cells were processed for RAD51
immunofluorescence. RAD51 foci were quantified (at least 400 cells were counted for
each cell). Data are represented as the mean 6 SEM (n = 3). (C) Artemis acts to prevent
end resection. HeLa cells were transfected with the indicated siRNAs. At 3 h post-
irradiation (10 Gy), cells were processed for RPA immunofluorescence. Shown is the
quantitation of RPA foci-positive cells (at least 400 cells were counted for each cell).
Data are represented as the mean 6 SEM (n = 3). (D) Artemis knockdown reduces radial
chromosomes in BRCA1-deficient cells. HeLa cells were transfected with the indicated
siRNAs and treated with 1 mM PARPis. Metaphases were analyzed for radial chromo-
somes (n = 50 metaphases analyzed in each case). Data are represented as the mean 6
SEM (n = 3). (E) The nuclease activity of Artemis is required for the prevention of end
resection and HR repair. HeLa cells were reconstituted with empty vector, siRNA-
resistant Artemis wild-type, or Artemis nuclease-inactive mutant (H35AD37N). Next,
HeLa cells as well as these reconstituted cells were transfected with the indicated
siRNAs and treated with 1 mM PARPis. Colony formation was quantified relative to
colonies formed in untreated cells from the same setting. (Left panel) Data are
represented as the mean 6 SEM (n = 3). (Top panel) Knockdown efficiency of Artemis
or BRCA1 was confirmed by Western blotting with the indicated antibodies. SFB empty
vector (Mock), SFB-tagged wild-type Artemis, and H35AD37N mutant Artemis were
transfected into 293T cells, and Artemis complexes were first pulled down by
streptavidin beads, then eluted by biotin buffer, and pulled down again by S protein
beads. (Bottom panel) In vitro nuclease assays of wild-type and H35AD37N mutant
Artemis were performed as described in the Materials and Methods.
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that works for immunostaining. Instead,
we showed that GFP-tagged Artemis was
recruited to DNA damage sites after laser-
inducedmicroirradiation (Fig. 4A). Next, we
determined whether this damage-induced
localization of Artemis required 53BP1 or
PTIP. To do that, we used the CRISPR/Cas9-
mediated gene-editing approach (Cong et al.
2013; Mali et al. 2013) to generate HeLa cell
lines that are specifically defective in 53BP1
or PTIP. We further established expression
of GFP-tagged Artemis in control or HeLa
knockout cell lines. As shown in Figure 4A,
we observed rapid accumulation of GFP-
Artemis at laser-induced DNA lesions
in wild-type, 53BP1 knockout, and PTIP
knockout HeLa cell lines. Furthermore,
continued time-lapse imaging for a period
of 2 h after microirradiation followed by
quantification of GFP-Artemis fluorescent
intensity revealed that the fluorescent in-
tensity of the accumulation area in HeLa
cells decreased to ;60% of the maximum
level in a 2-h duration (Fig. 4B). In contrast,
the Artemis fluorescent intensity was re-
duced to 20%–30% of the maximum level
in 53BP1 or PTIP knockout HeLa cells during
the same period. In addition, compared with
wild-type HeLa cells, 53BP1 knockout or
PTIP knockout HeLa cells displayed a sub-
stantial decrease of Artemis chromatin load-
ing following ionizing radiation (IR) treatment
(Fig. 4C). These results demonstrate that
53BP1 and PTIP are required for the reten-
tion of Artemis at DNA damage sites.
In this study, we showed that Artemis is
amajor nuclease that acts downstream from
the 53BP1 pathway and participates in the
prevention of DNA end resection, thereby
antagonizing HR repair (Fig. 4D). Mechanis-
tically, we demonstrated that Artemis binds
to PTIP and accumulates at sites of DNA
damage (Figs. 1B,C, 4A). The interaction
between PTIP and Artemis is phosphoryla-
tion-dependent and is induced by DNA
damage (Fig. 3A,C). Excitingly, just like
53BP1, loss of Artemis expression in
BRCA1-deficient cells leads to PARPi re-
sistance (Fig. 2A). Furthermore, loss of Ar-
temis increased RAD51 foci and RPA foci
formation in BRCA1-depleted cells (Fig. 2B,
C), indicating that Artemis normally acts to
limit end resection and inhibit RAD51-de-
pendent HR repair. We propose that this
function of Artemis is similar to its role in
V(D)J recombination. The nuclease activi-
ties of Artemis are important for its func-
tion in antagonizing HR repair (Fig. 2E). Our
working hypothesis is that the 53BP1/PTIP
pathway facilitates the accumulation of
Artemis at the sites of DNA damage. Arte-
mis acts as an endonuclease and trims DNA
ends to promote NHEJ and therefore at the
same time prevents end resection and HR
repair.
Figure 3. The interaction between PTIP and Artemis is phosphorylation-dependent,
and phosphorylation of Artemis is ATM-dependent. (A) PTIP/Artemis interaction is
phosphorylation-dependent. Beads coated with bacterially expressed GST-PTIP BRCT2
fusion protein were incubated with cell lysates containing exogenously expressed, SFB-
tagged Artemis that was mock-treated or treated with l protein phosphatase. Immu-
noblotting experiments were carried out with the indicated antibodies. (B) Alignment of
potential phospho-motif on Artemis among species. (C) Mapping the phosphorylation
site on Artemis that is important for its interaction with PTIP. Beads coated with
bacterially expressed GST-PTIP BRCT2 fusion protein or SFB-tagged Artemis were
incubated with cell lysates containing exogenously expressed, SFB-tagged wild-type or
mutant Artemis with or without IR (20 Gy). Immunoblotting experiments were carried
out using the indicated antibodies. (D) The PTIP/Artemis interaction is critical for
antagonizing HR repair. HeLa cells were reconstituted with empty vector, siRNA-
resistant Artemis wild type, or Artemis 6S/TAmutant. Next, HeLa cells as well as these
reconstituted cells were transfected with the indicated siRNAs and treated with 1 mM
PARPis. Colony formation was quantified relative to colonies formed in untreated cells
from the same setting. (Top panel) Data are represented as the mean 6 SEM (n = 3).
(Bottom panel) The knockdown efficiency of Artemis or BRCA1 was confirmed by
Western blotting with the indicated antibodies. (E) Endogenous PTIP interacts with
Artemis in a DNA damage-induced manner. HeLa cells were treated with or without IR
(20 Gy). HeLa cell lysates were prepared and immunoprecipitated with control or PTIP
antibody. Immunoprecipitates were blotted using antibodies as indicated. (F) The
interaction of Artemis with PTIP was induced by DNA damage, which is mainly
dependent on ATM kinase. Beads coated with bacterially expressed GST-PTIP BRCT2
fusion protein or SFB-tagged Artemis were incubated with cell lysates containing
exogenously expressed, SFB-tagged Artemis mock-treated or treated with ATM in-
hibitors (ATMi; KU60019), DNAPK inhibitors (DNAPKi; NU7026), and a combination
of ATM inhibitors and DNAPK inhibitors (ATMi+DNAPKi) with or without IR (20 Gy).
Immunoblotting experiments were carried out using the indicated antibodies.
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It remains uncertain whether Artemis is the only
nuclease that acts in the 53BP1 pathway. It will be
interesting to explore whether, like 53BP1, Artemis loss
would rescue embryonic lethality in BRCA1-deficient
mice. In addition, future studies should be devoted to
taking advantage of this knowledge and developing strat-
egies to overcome PARPi resistance in BRCA1 patients.
Materials and methods
Additional methods are described in the Supplemental Material.
Generation of DNA damage with laser microirradiation
Live-cell imaging combined with laser microirradiation was carried out as
described previously (Uematsu et al. 2007). Briefly, HeLa cells and 53BP1
knockout, PTIP knockout, and Artemis knockout HeLa
cells stably expressing EGFP-Artemis were grown on
glass-bottomed 35-mm dishes for 48 h. A 365-nm pulsed
nitrogen laser at 10 Hz (Spectra-Physics), coupled to the
epifluorescent path of a Zeiss microscope, was used to
introduce DNA damage in a defined area within the
nuclei of EGFP-Artemis-expressing cells. To generate
the same amount of DNA damage in each experiment,
we used optimal irradiation conditions (80% laser out-
put at 10 Hz for 400 msec). Time-lapse images of living
cells were taken by an Axiovert 200M microscope with
a Plan Apochromat 633/NA 1.40 oil immersion objec-
tive, equipped with an AxioCam HRm camera (Carl
Zeiss MicroImaging).
CRISPR–Cas9 gene-editing approach
to generate 53BP1 knockout, PTIP knockout,
and Artemis knockout HeLa cells
Vectors encoding guide RNA (gRNA) were digested with
AfIII, and a pair of annealed oligonucleotides for each
targeting site was cloned into the gRNA vector accord-
ing to the protocol (Cong et al. 2013). Designs were
chosen to target the gene in one of the first few exons
and were tested for obvious potential off-targets by
bioinformatics analysis. HeLa cells were transfected
with vectors expressing hCas9 gRNAs along with EGFP
expression vector. Cells were then sorted and seeded as
single colonies in 96-well plates. After 2–3wk, cloneswere
selected based on Western blotting with the appropriate
antibodies. In addition, genomic DNAwas extracted from
cell lines arising from single clones. PCR reactions to
amplify targeted loci were performed, and agarose gel
electrophoresis was used to confirm the correct size of
PCR products. PCR products were then cloned into the
pCR2.1-TOPO vector and transformed into DH5a compe-
tent cells. Plasmid DNA was isolated from multiple
colonies of each transformation and sequenced to ensure
frameshift mutations in the targeted region.
Chromatin extraction preparation
HeLa, 53BP1 knockout, and PTIP knockout cell lines
were harvested after treatment with or without IR (20
Gy) and subsequently lysed with 10 vol of NTEN buffer
with low salt (20 mM Tris-HCl at pH 8.0, 10 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 0.5% nonidet P-40, 20
mM NaF, 1mM Na3VO4, 1 mg/mL aprotinin, 1 mg/mL
pepstatin). The chromatin-enriched pellet was washed
three times with PBS. The insoluble chromatin fractions
were resuspended in 0.2 M HCl for 30 min on ice. The
resultant soluble extraction was neutralized with 1 M
Tris-HCl (pH 8.5) for further analysis.
In vitro nuclease activity assay
The in vitro nuclease assay was performed as previously reported (Goodarzi
et al. 2006). Briefly, to prepare the nuclease substrate, complementary
oligonucleotides (59-AAGCTTGCATGCCTGCAGGTCGACTTTTTTTTT
TTTTTT-39 and 59-GGTCGACCTGCAGGCATGCAAGCTT-39) were
annealed and labeled with 32P-a-dATP using polynucleotide kinase.
Radiolabeled oligonucleotides were purified and stored at 4°C in sterile
water. 293T cells transfected with SFB-tagged wild-type Artemis and
mutants of Artemis were lysed in lysis buffer (NETN + protease inhibitor).
The supernatant was incubated with streptavidin Sepharose beads on
a shaker for 1 h in a cold room after centrifugation. Beads were washed
three times with NETN buffer. Bound proteins were eluted with 2 mg/mL
biotin. Next, eluates were incubated with S beads on a shaker for 1 h in
a cold room. The wild-type Artemis and mutant of Artemis proteins were
incubated with buffer containing 25 mM Tris-HCl (pH 8.0), 10 mM
MgCl2, 1 mM DTT, 50 ng/mL BSA, ;0.15–0.25 pmol of 32P-labeled
DNA, 0.25 mM ATP, and 75 mM KCl. Reactions were carried out for 10
Figure 4. Artemis is a downstream effector of the 53BP1/PTIP-dependent pathway. (A)
Accumulation of Artemis at laser-induced DNA DSBs is reduced in 53BP1 knockout
(KO) and PTIP knockout cells. GFP-Artemis is stably expressed in HeLa, 53BP1
knockout, and PTIP knockout cells. DSBs were generated by microirradiation, and
GFP-Artemis accumulation was monitored before and after irradiation. A CRISPR/Cas9-
mediated gene-editing approach was used to generate a panel of HeLa cell lines
specifically defective in 53BP1 and PTIP, which was verified by Western blotting and
DNA sequence (data not shown). (B) Quantitative analysis of GFP-Artemis accumula-
tion at DSBs in HeLa, 53BP1 knockout, and PTIP knockout cell lines. Signal intensities
were quantified, and a mean value for each time point was calculated from five
independent measurements. (C) Both 53BP1 and PTIP are required for Artemis
chromatin loading following IR treatment. HeLa, 53BP1 knockout, and PTIP knockout
cell lines were treated with or without IR (20 Gy). Cells were harvested. The soluble and
chromatin fractions were prepared and immunoblotted with antibodies as indicated. (D)
A revised model of Artemis functions downstream from 53BP1/PTIP to counteract HR
repair.
Artemis directs DNA repair pathway choice
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min at 37°C before being stopped with 5 mL of formamide loading buffer
(96% [v/v] formamide, 10 mM EDTA at pH 8.0, 0.2% Orange-G dye),
incubated for 1 min at 100°C, and cooled rapidly on ice. DNA fragments
were resolved at 300 V on 0.5-mm thick, 15% PAGE minigels containing
13 TBE buffer and 7 M urea. Resolved gels were fixed in 10% (v/v)
methanol and 10% (v/v) acetic acid before being dried and exposed to film.
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